[Journal logo]

Volume 66 
Part 3 
Page o555  
March 2010  

Received 2 February 2010
Accepted 2 February 2010
Online 6 February 2010

Key indicators
Single-crystal X-ray study
T = 100 K
Mean [sigma](C-C) = 0.002 Å
R = 0.038
wR = 0.102
Data-to-parameter ratio = 16.1
Details
Open access

1,5-Bis[(E)-1-(2-hydroxyphenyl)ethylidene]thiocarbonohydrazide monohydrate

aDepartment of Chemistry, Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, 94300 Kota Samarahan, Sarawak, Malaysia, and bDepartment of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia
Correspondence e-mail: Edward.Tiekink@gmail.com

In the title compound, C17H18N4O2S·H2O, the thiourea derivative is almost planar, with an r.m.s. deviation for the non-H atoms of 0.057 Å. The hydroxyl groups lie to the same side of the molecule as the thione S atom, a conformation that allows the formation of intramolecular O-H...S and O-H...N hydrogen bonds. In the crystal structure, the thiourea and water molecules self-assemble into a two-dimensional array by a combination of Owater-H...Ohydroxyl, N-H...Owater and Owater-H...S hydrogen bonds and C-H...[pi] interactions.

Related literature

For background and recent studies of the biological activity of organotin compounds, see: Gielen & Tiekink (2005[Gielen, M. & Tiekink, E. R. T. (2005). Editors. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine, pp. 421-439. Chichester: John Wiley & Sons.]); Affan et al. (2009[Affan, M. A., Foo, S. W., Jusoh, I., Hanapi, S. & Tiekink, E. R. T. (2009). Inorg. Chim. Acta, 362, 5031-5037.]). For the structure of the ketone analogue of the title compound, see: Zukerman-Schpector et al. (2009[Zukerman-Schpector, J., Affan, M. A., Foo, S. W. & Tiekink, E. R. T. (2009). Acta Cryst. E65, o2951.]).

[Scheme 1]

Experimental

Crystal data
  • C17H18N4O2S·H2O

  • Mr = 360.43

  • Monoclinic, P 21 /n

  • a = 15.8654 (3) Å

  • b = 7.3938 (1) Å

  • c = 16.3697 (3) Å

  • [beta] = 115.922 (1)°

  • V = 1727.06 (5) Å3

  • Z = 4

  • Mo K[alpha] radiation

  • [mu] = 0.21 mm-1

  • T = 100 K

  • 0.44 × 0.13 × 0.07 mm

Data collection
  • Bruker SMART APEXII CCD diffractometer

  • Absorption correction: multi-scan (SADABS; Sheldrick, 1996[Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.]) Tmin = 0.905, Tmax = 1

  • 15464 measured reflections

  • 3968 independent reflections

  • 3136 reflections with I > 2[sigma](I)

  • Rint = 0.033

Refinement
  • R[F2 > 2[sigma](F2)] = 0.038

  • wR(F2) = 0.102

  • S = 1.03

  • 3968 reflections

  • 246 parameters

  • 7 restraints

  • H atoms treated by a mixture of independent and constrained refinement

  • [Delta][rho]max = 0.35 e Å-3

  • [Delta][rho]min = -0.27 e Å-3

Table 1
Hydrogen-bond geometry (Å, °)

Cg1 is the centroid of the C4-C9 ring.

D-H...A D-H H...A D...A D-H...A
O1-H1O...N2 0.83 (2) 1.79 (2) 2.5191 (17) 147 (2)
O1-H1O...S1 0.83 (2) 2.86 (2) 3.5126 (13) 138 (2)
O2-H2O...N4 0.82 (2) 1.81 (2) 2.542 (2) 148 (2)
O2-H2O...S1 0.82 (2) 2.96 (2) 3.6220 (15) 139 (2)
O3-H3O...O1 0.84 (2) 1.91 (2) 2.7525 (18) 174 (2)
O3-H4O...S1i 0.82 (2) 2.76 (2) 3.5089 (14) 154 (2)
N1-H1N...O3ii 0.87 (2) 2.04 (2) 2.8169 (19) 150 (2)
N3-H3N...O3ii 0.88 (2) 2.04 (2) 2.854 (2) 154 (2)
C11-H11C...Cg1iii 0.98 2.61 3.4497 (17) 144
Symmetry codes: (i) [-x+{\script{3\over 2}}, y-{\script{1\over 2}}, -z+{\script{3\over 2}}]; (ii) [x-{\script{1\over 2}}, -y+{\script{1\over 2}}, z-{\script{1\over 2}}]; (iii) -x+1, -y+1, -z+1.

Data collection: APEX2 (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2007[Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXS86 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: ORTEP-3 (Farrugia, 1997[Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.]) and DIAMOND (Brandenburg, 2006[Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.]); software used to prepare material for publication: SHELXL97.


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HB5327 ).


Acknowledgements

The authors express their gratitude to the Ministry of Science, Technology and Innovation (MOSTI) for a research grant (No. 06-01-09-SF0046), and to Universiti Malaysia Sarawak (UNIMAS) for financial support.

References

Affan, M. A., Foo, S. W., Jusoh, I., Hanapi, S. & Tiekink, E. R. T. (2009). Inorg. Chim. Acta, 362, 5031-5037.  [ISI] [CSD] [CrossRef]
Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.
Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.  [CrossRef] [details]
Gielen, M. & Tiekink, E. R. T. (2005). Editors. Metallotherapeutic Drugs and Metal-Based Diagnostic Agents: The Use of Metals in Medicine, pp. 421-439. Chichester: John Wiley & Sons.
Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Zukerman-Schpector, J., Affan, M. A., Foo, S. W. & Tiekink, E. R. T. (2009). Acta Cryst. E65, o2951.  [CrossRef] [details]


Acta Cryst (2010). E66, o555  [ doi:10.1107/S1600536810004241 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.